HMG-CoA还原酶抑制剂对2型糖尿病病人的血脂影响  

EFFECT OF INHIBITOR OF HMG_CoA REDUCTASE ON DYSLIPIDEMIA IN TYPE 2 DIABETES MELLITUS PATIENTS

作　　者：梁奕铨[1] 余斌杰[1] 肖亦斌[1] 

机构地区：[1]中山医科大学附属第一医院内分泌科

出　　处：《中华内分泌代谢杂志》1997年第4期229-232,共4页Chinese Journal of Endocrinology and Metabolism

摘　　要：我们观察了羟甲基戊二酰辅酶Ａ（ＨＭＧＣｏＡ）还原酶抑制剂乐瓦停对３１例胆固醇增高的２型糖尿病病人的降胆固醇作用，结果显示每日睡前服乐瓦停２０ｍｇ，３个月后平均降低血清总胆固醇３０．５％、低密度脂蛋白胆固醇２９．８％，并对高密度脂蛋白胆固醇降低者有升高其高密度脂蛋白胆固醇的作用；同时也有明显的降低载脂蛋白Ｂ１００（Ｐ＜０．０１）和载脂蛋白ＣＩＩＩ（Ｐ＜０．０５）的作用，但对载脂蛋白ＡＩ与载脂蛋白ＡＩＩ水平无影响。在观察期间未发现对血糖与糖基化血红蛋白Ａ１ｃ有影响，提示在２型糖尿病病人中。The effect of lovastatin, a potent inhibitor of 3_hydroxy_3_methylglutaryl_coenzyme A reductase was assessed in 31 type 2 diabetes mellitus patients with moderate elevation of plasma cholesterol. Each patient received 20mg of lovastatin peroral daily for 3 months. The results showed that lovastatin reduced total cholesterol by 30.5% and low_density lipoprotein cholesterol (LDL_C) by 29.8%. Lovastatin therapy also reduced apolipoprotein B100 and apolipoprotein CIII and elevated high_density lipoprotein cholesterol level in type 2 diabetes mellitus patients with hypohigh_density lipoprotein cholesterol and glycemic control was well_maintained. However, Lovastatin had no effect on apolipoprotein AI and apolipoprotein AII. No side effects or abnormalities in serum hepatic enzyme concentration or CPK were noted during short_term lovastatin therapy. The data suggest that lovastatin has beneficial effect to decrease plasma cholesterol level in patients with type 2 diabetes mellitus.

关 键 词：糖尿病 载脂蛋白 还原酶 抑制剂 HMG-COA 

分 类 号：R587.1[医药卫生—内分泌]